. Author manuscript; available in PMC: 2019 Apr 9.

Published in final edited form as: Liver Int. 2016 Mar 24;36(6):807–816. doi: 10.1111/liv.13102

Table 2.

Association between baseline variables and SVR12

Baseline characteristics	Univariate		Multivariate
Baseline characteristics	IRR (95% CI)	P-value	IRR (95% CI)	P-value

eGFR ≤45 (vs. eGFR >45)	0.95(0.81–1.12)	0.56	0.95(0.80–1.12)	0.52
Male (vs. female)	0.90(0.85–0.96	0.001	0.92 (0.87–0.98)	0.01
Black or AA race (vs. non-Black or non-AA)	0.92(0.83–1.02)	0.13	0.89 (0.80–0.98)	0.02
Genotype 1 (vs. non-1)	1.08(1.01–1.17)	0.03	1.02 (0.94–1.12)	0.60
Prior HCV treatment (vs. treatment naïve)	0.93(0.87–0.99)	0.01	0.93 (0.88–0.99)	0.02
Cirrhosis (vs. no cirrhosis)	0.87(0.82–0.93)	<0.001	0.86 (0.80–0.91)	<0.001
Any transplant^* (vs. non-transplant)	0.95(0.86–1.05)	0.33	0.95 (0.86–1.06)	0.36
RBV-free regimenf^† (vs. RBV-containing regimens)	1.20(1.13–1.27)	<0.001	1.22 (1.13–1.31)	<0.001

Includes liver alone transplant, kidney alone transplant and simultaneous liver–kidney transplant.

^†

Includes patients treated with SOF/SMV vs. those treated with SOF/PEG/RBV, SOF/RBV, SOF/SMV/RBV.

AA, African American; HCV, hepatitis C virus; IRR, incident rate ratio; RBV, ribavirin.

Bold text signifies results for primary predictor and for statistically significant covariates in multivariate model.